Pogues: a solid announcement with good scientific information. Timelines: years away as they have a monumental task. However the plan will be to develop the Oromist delivery, without cardio stimulation and hopefully sell to a pharma who concentrates on cancer drugs, who will develop to trials and commercialisation. Well done management.
SUD Price at posting:
0.5¢ Sentiment: Buy Disclosure: Held